Foravirumab

Foravirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	rabies virus glycoprotein
Clinical data
ATC code	none
Identifiers
CAS Number	944548-38-3^N
ChemSpider	none
UNII	377VY97V7S
ChEMBL	CHEMBL1743021^N
Chemical and physical data
Formula	C₆₄₀₀H₉₉₁₄N₁₇₁₈O₁₉₉₈S₄₄
Molar mass	144.3 kg/mol
^NY (what is this?) (verify)

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.^[1] It is under development by Sanofi/Crucell.^[2]

References

↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
↑ Khardori, Nancy Misri (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 9781455712076.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab^†

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab^§ Exbivirumab^§ Foravirumab^§ Libivirumab^§ Nirsevimab^§ Rafivirumab^§ Regavirumab^§ Sevirumab^† Suptavumab Tuvirumab^§
Chimeric ("-vixi-")	Cosfroviximab Larcaviximab Porgaviximab
Humanized ("-vizu-")	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab^§ Raxibacumab
Mouse ("-baco-")	Edobacomab^§
Chimeric ("-baxi-")	Pagibaximab^†
Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric ("-toxaxi-")	Obiltoxaximab
Humanized ("-toxazu-")	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.